Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 798742, 17 pages
http://dx.doi.org/10.1155/2014/798742
Research Article

Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine

1Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2Department of Medicine, China Medical University, Taichung 40402, Taiwan
3Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 40402, Taiwan
4Human Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan

Received 21 February 2014; Revised 5 March 2014; Accepted 5 March 2014; Published 19 June 2014

Academic Editor: Chung Y. Hsu

Copyright © 2014 Hsin-Chieh Tang and Calvin Yu-Chian Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Spencer, S. D. Cappell, F. C. Tsai, K. W. Overton, L. Cl. Wang, and T. Meyer, “The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit,” Cell, vol. 155, no. 2, pp. 369–383, 2013. View at Publisher · View at Google Scholar
  2. R. A. Weinberg, “The retinoblastoma protein and cell cycle control,” Cell, vol. 81, no. 3, pp. 323–330, 1995. View at Google Scholar · View at Scopus
  3. A. W. Murray and M. W. Kirschner, “Dominoes and clocks: the union of two views of the cell cycle,” Science, vol. 246, no. 4930, pp. 614–621, 1989. View at Google Scholar · View at Scopus
  4. L. H. Hartwell and T. A. Weinert, “Checkpoints: controls that ensure the order of cell cycle events,” Science, vol. 246, no. 4930, pp. 629–634, 1989. View at Google Scholar · View at Scopus
  5. A. Kamb, N. A. Gruis, J. Weaver-Feldhaus et al., “A cell cycle regulator potentially involved in genesis of many tumor types,” Science, vol. 264, no. 5157, pp. 436–440, 1994. View at Google Scholar · View at Scopus
  6. C. Dehay and H. Kennedy, “Cell-cycle control and cortical development,” Nature Reviews Neuroscience, vol. 8, no. 6, pp. 438–450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. van den Heuvel and E. Harlow, “Distinct roles for cyclin-dependent kinases in cell cycle control,” Science, vol. 262, no. 5142, pp. 2050–2054, 1993. View at Google Scholar · View at Scopus
  8. L. H. Hartwell, J. J. Hopfield, S. Leibler, and A. W. Murray, “From molecular to modular cell biology,” Nature, vol. 402, supplement 6761, pp. C47–C52, 1999. View at Google Scholar · View at Scopus
  9. L. R. Bandara, J. P. Adamczewski, T. Hunt, and N. B. La Thangue, “Cyclin A and the retinoblastoma gene product complex with a common transcription factor,” Nature, vol. 352, no. 6332, pp. 249–251, 1991. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Nurse, “Ordering S phase and M phase in the cell cycle,” Cell, vol. 79, no. 4, pp. 547–550, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge, “The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases,” Cell, vol. 75, no. 4, pp. 805–816, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Waga, G. J. Hannon, D. Beach, and B. Stillman, “The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA,” Nature, vol. 369, no. 6481, pp. 574–578, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Xiong, G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach, “p21 is a universal inhibitor of cyclin kinases,” Nature, vol. 366, no. 6456, pp. 701–704, 1993. View at Google Scholar · View at Scopus
  14. G. J. Hannon and D. Beach, “p15INK4B is a potential effector of TGF-β-induced cell cycle arrest,” Nature, vol. 371, no. 6494, pp. 257–261, 1994. View at Google Scholar · View at Scopus
  15. I. Hatada and T. Mukai, “Genomic imprinting of p57(KIP2), a cyclin-dependent kinase inhibitor, in mouse,” Nature Genetics, vol. 11, no. 2, pp. 204–206, 1995. View at Google Scholar · View at Scopus
  16. L. A. Garraway, H. R. Widlund, M. A. Rubin et al., “Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma,” Nature, vol. 436, no. 7047, pp. 117–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Du, H. R. Widlund, M. A. Horstmann et al., “Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF,” Cancer Cell, vol. 6, no. 6, pp. 565–576, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Bittner, P. Meltzer, Y. Chen et al., “Molecular classification of cutaneous malignant melanoma by gene expression profiling,” Nature, vol. 406, no. 6795, pp. 536–540, 2000. View at Publisher · View at Google Scholar
  19. A. J. Miller and M. C. Mihm Jr., “Melanoma,” The New England Journal of Medicine, vol. 355, no. 1, pp. 51–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Gogas, J. Ioannovich, U. Dafni et al., “Prognostic significance of autoimmunity during treatment of melanoma with interferon,” The New England Journal of Medicine, vol. 354, no. 7, pp. 709–718, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Hodis, I. R. Watson, G. V. Kryukov et al., “A landscape of driver mutations in melanoma,” Cell, vol. 150, no. 2, pp. 251–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Shi, G. Moriceau, X. Kong et al., “Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance,” Nature Communications, vol. 3, article 724, 2012. View at Publisher · View at Google Scholar
  24. P. I. Poulikakos, Y. Persaud, M. Janakiraman et al., “RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E),” Nature, vol. 480, no. 7377, pp. 387–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Nazarian, H. Shi, Q. Wang et al., “Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation,” Nature, vol. 468, no. 7326, pp. 973–977, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. M. Johannessen, J. S. Boehm, S. Y. Kim et al., “COT drives resistance to RAF inhibition through MAP kinase pathway reactivation,” Nature, vol. 468, no. 7326, pp. 968–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. P. J. Stephens, P. S. Tarpey, H. Davies et al., “The landscape of cancer genes and mutational processes in breast cancer,” Nature, vol. 486, no. 7403, pp. 400–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Malumbres and M. Barbacid, “Cell cycle, CDKs and cancer: a changing paradigm,” Nature Reviews Cancer, vol. 9, no. 3, pp. 153–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Georgieva, P. Sinha, and D. Schadendorf, “Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions,” Journal of Clinical Pathology, vol. 54, no. 3, pp. 229–235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Abdullah, X. Wang, and D. Becker, “Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma: functional analysis and molecular targeting of cyclin-dependent kinase family members in advanced melanoma,” Cell Cycle, vol. 10, no. 6, pp. 977–988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. B. M. Desai, J. Villanueva, T.-T. K. Nguyen et al., “The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling,” PLoS ONE, vol. 8, no. 3, Article ID e59588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. C.-H. Wang, W.-D. Lin, and F.-J. Tsai, “Craniofacial dysmorphism, what is your diagnosis?” BioMedicine, vol. 2, no. 2, pp. 49–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. W.-L. Liao and F.-J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013. View at Publisher · View at Google Scholar
  34. I.-C. Chou, W.-D. Lin, C.-H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. T.-T. Chang, M.-F. Sun, H.-Y. Chen et al., “Screening from the world's largest TCM database against H1N1 virus,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 5, pp. 773–786, 2011. View at Google Scholar · View at Scopus
  37. W. I. Tou, S.-S. Chang, C.-C. Lee, and C. Y.-C. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, article 844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. H.-C. Tang and C. Y.-C. Chen, “Investigation of the novel lead of melanocortin 1 receptor for pigmentary disorders,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 254678, 13 pages, 2014. View at Publisher · View at Google Scholar
  39. T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. K.-C. Chen, M.-F. Sun, S.-C. Yang et al., “Investigation into potent inflammation inhibitors from traditional Chinese medicine,” Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K.-C. Chen and C. Y.-C. Chen, “Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach,” Soft Matter, vol. 7, no. 8, pp. 4001–4008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Tian, J. Wang, Y. Li, X. Xu, and T. Hou, “Drug-likeness analysis of traditional chinese medicines: prediction of drug-likeness using machine learning approaches,” Molecular Pharmaceutics, vol. 9, no. 10, pp. 2875–2886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S.-C. Yang, S.-S. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. K.-C. Chen, S.-S. Chang, H.-J. Huang, T.-L. Lin, Y.-J. Wu, and C. Y.-C. Chen, “Three-in-one agonists for PPAR-a, PPAR-γ, and PPAR-d from traditional Chinese medicine,” Journal of Biomolecular Structure & Dynamics, vol. 30, no. 6, pp. 662–683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Y.-C. Chen, “TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. K. F. Byth, N. Cooper, J. D. Culshaw et al., “Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 9, pp. 2249–2252, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Y.-C. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” Drug Discovery Today, vol. 18, pp. 910–915, 2013. View at Publisher · View at Google Scholar
  48. W. I. Tou and C. Y.-C. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, vol. 19, no. 4, pp. 367–372, 2014. View at Publisher · View at Google Scholar
  49. T. H. Keller, A. Pichota, and Z. Yin, “A practical view of “druggability’,” Current Opinion in Chemical Biology, vol. 10, no. 4, pp. 357–361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Ganesan, “The impact of natural products upon modern drug discovery,” Current Opinion in Chemical Biology, vol. 12, no. 3, pp. 306–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. B. R. Brooks, C. L. Brooks III, A. D. Mackerell Jr. et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Y.-C. Chen, “A novel integrated framework and improved methodology of computer-aided drug design,” Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965–988, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Y.-C. Chen, “Weighted equation and rules—a novel concept for evaluating protein-ligand interaction,” Journal of Biomolecular Structure & Dynamics, vol. 27, no. 3, pp. 271–282, 2009. View at Google Scholar · View at Scopus
  54. S. K. Tripathi, R. Muttineni, and S. K. Singh, “Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors,” Journal of Theoretical Biology, vol. 334, pp. 87–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. M. T. H. Khan, “Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches,” Current Drug Metabolism, vol. 11, no. 4, pp. 285–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. D. van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. C. Berendsen, “GROMACS: fast, flexible, and free,” Journal of Computational Chemistry, vol. 26, no. 16, pp. 1701–1718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. V. N. Maiorov and G. M. Crippen, “Size-independent comparison of protein three-dimensional structures,” Proteins: Structure, Function and Genetics, vol. 22, no. 3, pp. 273–283, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Chovancova, A. Pavelka, P. Benes et al., “CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures,” PLoS Computational Biology, vol. 8, no. 10, Article ID e1002708, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. A. P. Kumar, S. Bhaskaran, M. Ganapathy et al., “Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract,” Clinical Cancer Research, vol. 13, no. 9, pp. 2784–2794, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. A. James, H. Fu, Y. Liu, D.-R. Chen, and M. You, “Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis,” Molecular Carcinogenesis, vol. 50, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. G.-B. Jin, T. Hong, S. Inoue et al., “Augmentation of immune cell activity against tumor cells by Rauwolfia radix,” Journal of Ethnopharmacology, vol. 81, no. 3, pp. 365–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. J.-L. Gao, J.-M. Shi, K. He et al., “Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways,” Oncology Reports, vol. 20, no. 4, pp. 819–824, 2008. View at Publisher · View at Google Scholar · View at Scopus